Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for ...

No new safety signals observed at Year 5 in the POETYK ... the first TYK2 inhibitor available for patients living with moderate-to-severe plaque psoriasis, as a potential oral standard of care.” ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Safety professionals save lives and increase organizational effectiveness every day. In our Occupational Health and Safety Management program, you will study various concepts and principles from ...

Some of the most common reasons include: According to the World Health Organization (WHO), up to 4% of the world’s population experiences 15 or more headache days a month. If you are one of these ...

Current healthcare reforms have increased the demand for public health educators, health promotion specialists, and allied health professionals. The University of Houston’s Bachelor of Science Health ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial ... “These results further support the role of Sotyktu, the first TYK2 inhibitor available for patients living with ...

The Queen has praised the “brilliant” efforts of health workers and other staff supporting sexual assault victims at a specialist centre she officially opened ... She told the staff assembled for a ...

Reducing plaque buildup and managing high cholesterol is achievable through a combination of dietary changes, physical activity. However, it is essential to get regular health check up to ...